AnaptysBio, Inc. has grown revenue 164% a year over three years and 19% a year over five. Revenue growth, 3-year annual rate: +164% (Biotechnology median +17%). Revenue growth, 5-year rate: +19%, growth has picked up over the last three years. Years of annual history on file: 11, FY2015 to FY2025, as filed.

ANABAnaptysBio, Inc.

Healthcare

$45.97+231% 1Y

$45.97

$13.9752 weeks$69.82

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +93% year on year and operating margin widening (+68.9 points), but earnings down −236% year on year.

2 good, 1 to watch

Revenue trend+93% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +19% a year.

Earnings trend−236% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction+68.9 points operating

Trailing-twelve-month operating margin, 95.2% now against 26.3% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearstop 1% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ANAB growing?

AnaptysBio, Inc. has grown revenue 164% a year over three years and 19% a year over five.

+164%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +19%
Revenue growth, 5-year rate · +164% over three · growth has picked up over the last three years
Years of annual history on file: 11
Years of annual history on file · FY2015 to FY2025, as filed

Details›